Neurology Central

Tandem autologous stem cell transplant may improve neuroblastoma survival

In general, less than 50% of children with high risk neuroblastoma survive for longer than 5 years following a diagnosis. However, the results of a Phase III trial presented this week at the American Society of Clinical Oncology Annual Meeting (3–7th June 2016, IL, USA) has indicated that the addition of a second autologous stem cell transplant (ASCT), utilizing the patient’s own stem cells, could improve survival outcomes.

Children with a median age of 3.1 years that had been newly diagnosed with high-risk neuroblastoma were enrolled onto the trial. Of the patients, 88% had Stage 4 disease and 38.2% had a tumor with MYCN amplification, a high risk genetic abnormality.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.